Lipocine Inc. (LPCN)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
📈 **POSITIVE** • Medium confidence analysis (66%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (81%) **Content type:** Clinical